Glycitop 80mg Tablet contains Gliclazide, a sulfonylurea class oral hypoglycemic agent used in the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glycitop is indicated as an adjunct to diet and exercise to achieve better blood glucose regulation when these measures alone are insufficient. The 80mg dosage is typically administered once or twice daily, depending on the patient’s glycemic response and physician’s discretion. Gliclazide has a relatively lower risk of hypoglycemia compared to other sulfonylureas due to its selective action on pancreatic receptors. Patients should be monitored regularly for blood glucose levels and signs of hypoglycemia. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and allergic reactions. Glycitop should be used under medical supervision with appropriate lifestyle modifications to optimize therapeutic outcomes and minimize complications associated with diabetes mellitus.